Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib

David Hong; Lei Ye; Robert Gagel; Lakshmi Chintala; Adel K. El Naggar; John Wright; Razelle Kurzrock

doi:10.1158/1535-7163.MCT-07-2422

Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib

David Hong, Lei Ye, Robert Gagel, Lakshmi Chintala, Adel K. El Naggar, John Wright, Razelle Kurzrock

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor) - based regimen in a patient with sporadic MTC who had advanced, progressive disease and a novel RET kinase aberration at exon 11 shown in tumor tissue.

Original language	English (US)
Pages (from-to)	1001-1006
Number of pages	6
Journal	Molecular cancer therapeutics
Volume	7
Issue number	5
DOIs	https://doi.org/10.1158/1535-7163.MCT-07-2422
State	Published - 2008

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1535-7163.MCT-07-2422

Cite this

@article{7bc57f08c1fb4d508ef654addc389dfe,

title = "Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib",

abstract = "Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor) - based regimen in a patient with sporadic MTC who had advanced, progressive disease and a novel RET kinase aberration at exon 11 shown in tumor tissue.",

author = "David Hong and Lei Ye and Robert Gagel and Lakshmi Chintala and {El Naggar}, {Adel K.} and John Wright and Razelle Kurzrock",

year = "2008",

doi = "10.1158/1535-7163.MCT-07-2422",

language = "English (US)",

volume = "7",

pages = "1001--1006",

journal = "Molecular cancer therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

TY - JOUR

T1 - Medullary thyroid cancer

T2 - Targeting the RET kinase pathway with sorafenib/tipifarnib

AU - Hong, David

AU - Ye, Lei

AU - Gagel, Robert

AU - Chintala, Lakshmi

AU - El Naggar, Adel K.

AU - Wright, John

AU - Kurzrock, Razelle

PY - 2008

Y1 - 2008

N2 - Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor) - based regimen in a patient with sporadic MTC who had advanced, progressive disease and a novel RET kinase aberration at exon 11 shown in tumor tissue.

AB - Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor) - based regimen in a patient with sporadic MTC who had advanced, progressive disease and a novel RET kinase aberration at exon 11 shown in tumor tissue.

UR - http://www.scopus.com/inward/record.url?scp=49849083911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849083911&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-2422

DO - 10.1158/1535-7163.MCT-07-2422

M3 - Article

C2 - 18445656

AN - SCOPUS:49849083911

SN - 1535-7163

VL - 7

SP - 1001

EP - 1006

JO - Molecular cancer therapeutics

JF - Molecular cancer therapeutics

IS - 5

ER -

Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this